Although each of these processes is typically considered to be a distinct entity, such distinctions are in some ways arbitrary and can ultimately be misleading -in the context of TBI, many of them proceed more or less simultaneously, some may trigger or otherwise exacerbate others, and none is completely unique molecularly. In addition, the specific combination and magnitude of secondary mechanisms that are elicited by any given injury vary with the actual biomechanics of the initial injury process.
The goal of treatment in TBI is to ameliorate progression of secondary injury. Numerous neuroprotective compounds have been investigated for TBI [1] . A recent review concluded that nearly all phase II/III clinical trials in neuroprotection have failed to show any consistent improvement in outcome for TBI patients [13] . Because the pathology of CNS trauma involves so many different but intertwined mechanisms, disappointing outcomes have resulted in calls to consider targeting multiple injury mechanisms simultaneously [14, 15] . An alternative approach is to prevent an early secondary event that is critical for triggering or exacerbating other mechanisms of secondary injury that unfold later. A prominent example of such an early key event is secondary hemorrhage. Known in the vernacular as 'blossoming' of a contusion, secondary hemorrhage is certainly one of the most devastating forms of secondary injury since many other secondary injury processes are initiated or exacerbated by the extravasated blood, including oxidative stress, inflammation, edema, cell death, mass effect, and increased intracranial pressure (ICP). Reducing secondary hemorrhage after CNS trauma may have profound effects on overall outcome [16 ] .
The idea of 'neuroprotection' in TBI continues to be dominated by a neurocentric view. Similar to concepts brought forth in the stroke literature over the last several years, there is a growing recognition that 'supporting cells' in the brain play vital roles in the overall response to injury. Microglia, astrocytes, oligodendrocytes, and endothelial cells certainly are critical to the survival and well being of neurons. It is not trivial to say that, without oligodendrocytes, communication between neurons is largely impossible, regardless of the status of the axon. Similarly, the microvasculature plays an absolutely central role: without a healthy functioning microvasculature, ischemia/reperfusion injury occurs that threatens all other cells. With a 'reactive' microvasculature, there is transcapillary flow of plasma that forms 'vasogenic' edema and transcapillary passage of inflammatory cells that incite bystander injury, with both of these events threatening all other cells. Moreover, if activated microvascular cells undergo oncotic/necrotic death, matrix metalloproteinases are released that degrade the microvascular basement membrane, leading to secondary hemorrhage. There is ample reason to believe that one of the best ways to protect neurons is to promote a healthy, nonreactive microvasculature.
Given these complexities, it is inevitable that even the most sharply focused molecular approach for preventing secondary injury will inevitably influence multiple secondary mechanisms. For this reason, the following brief review is organized around pharmaceutical agents, rather than specifically around presumed molecular target(s). Due to space limitations, only a limited number of promising agents currently under study can be mentioned. These agents -all focused on treatments during the acute stage -have shown efficacy not only in preclinical models, but also in human trials, either prospective or retrospective. (Details on clinical trials involving most of the agents listed below may be found at http:// www.ninds.nih.gov/research/tbi/index.htm). It is notable that in several instances the drug targets a broad physiological mechanism (tranexamic acid, vasopressin, propofol, citicholine) or a mechanism that is poorly understood (progesterone). Three agents are mentioned that target a specific molecular mechanism directly linked to TBI (darbapoetin, cyclosporine, and glyburide).
Tranexamic acid
Progressive secondary hemorrhage is associated with especially poor outcome in TBI (see discussion in citation) [16 ] . One of the potential underlying mechanisms is a clinical or subclinical coagulopathy. The antifibrinolytic agent, tranexamic acid, which has significant clinical benefit in reducing surgical bleeding [17] , has no effect on coagulation parameters and no demonstrated harmful effects. Tranexamic acid is being examined to determine its effectiveness in preventing secondary hemorrhage in patients with moderate-to-severe TBI.
Vasopressin
To minimize ischemia, several current treatments attempt to optimize cerebral perfusion pressure (CPP), including mannitol to reduce ICP and catecholamines, such as phenylephrine, to increase mean arterial pressure. During fluid resuscitation, arginine vasopressin rapidly restores hemodynamics, CPP, and improved acute survival in a clinically relevant model of TBI. Similar shortterm benefits have been observed in humans after chest and liver trauma. Vasopressin is being examined to evaluate its efficacy in CPP management in patients with TBI. However, vasopressin V(1A) receptors are involved in the pathogenesis of brain edema formation in TBI [18] , which could compromise the anticipated beneficial effects related to CPP. maintain cerebral perfusion and includes deep anesthesia. Propofol was recently shown to have antioxidant properties. Propofol is being compared with midazolam to determine whether its anesthetic effect is supplemented by a reduction in intracerebral oxidative stress following severe TBI.
CDP-choline (citicoline; COBRIT)
Choline precursors promote repair and growth of cell membranes and hold promise in a variety of neurologic diseases, including ischemic and hemorrhagic stroke and TBI. Citicoline, the most well studied choline agent precursor, is widely prescribed throughout the world and recently became available in the United States as a dietary supplement. In experimental stroke models, citicoline confers acute neuroprotection and enhanced neuroplasticity and neurorepair. Although individual human stroke trials have been inconclusive, metaanalysis of 10 trials enrolling 2279 patients suggests patients receiving citicoline had substantially reduced frequencies of death and disability [19, 20] .
Progesterone
Progesterone provides neuroprotection by decreasing cerebral edema, protecting the blood-brain barrier, down-regulating the inflammatory cascade, and limiting cellular necrosis and apoptosis [21] [22] [23] [24] . Clinical studies to date also suggest a protective effect of progesterone [25, 26 ] . However, in a recent rodent study, progesterone failed to alter edema and tissue sparing [27] , and in recent human studies, progesterone failed to reduce ICP, calling in to question the precise mechanism(s) of secondary injury affected by progesterone [25, 26 ] . Progesterone may also help in sparing white matter [28, 29] .
Darbepoetin (long-acting erythropoetin)
Erythropoietin and erythropoietin receptors are upregulated after TBI and are important in neuroprotection [30] . Erythropoietin and some of its variants cross the blood-brain barrier, stimulate neurogenesis and neuronal differentiation, and activate brain neurotrophic, antiapoptotic, antioxidant, and anti-inflammatory signaling. Erythropoietin protects neurons in models of ischemic and traumatic degenerative damage due to exocitotoxins and consequent generation of free radicals including nitric oxide. Erythropoietin restores brain mitochondrial function after TBI, resulting in enhanced cellular energy generation and reduced oxidative stress [31] . Erythropoietin receptor activation also prevents the indiscriminate exocytosis of glutamate in a model of chemically induced ischemia on neurons of rat hippocampus [30] .
Cyclosporin
The mitochondrion is one of the major targets of TBI, as seen by changes in mitochondrial permeability transition, release of cytochrome c, caspase activation, reduced ATP levels, and cell death in neurons [32] . Involvement of mitochondria in acute post-traumatic neurodegeneration has been extensively studied during the last decade, and a number of investigations implicate the activation of the mitochondrial permeability transition pore (mPTP) as a 'critical switch' that determines cell survival after TBI. Cyclosporin A, which blocks the opening of mPTP, showed a significant decrease in mitochondrial damage and intra-axonal cytoskeletal destruction. A recent study showed that, at 6 months, a significant dose-related improvement in favorable outcome was observed in cyclosporine-treated TBI patients [33] .
Glyburide
Edema and progressive secondary hemorrhage are highly significant causes of morbidity and mortality. In CNS ischemia and TBI, these mechanisms of secondary injury may be due to up-regulation of SUR1-regulated NC Ca-ATP channels in microvascular endothelium [34] . Blocking these channels with the SUR1 inhibitor, glibenclamide, reduced edema, secondary hemorrhage, inflammation, apoptosis, lesion size, and mortality in preclinical studies [16 ,35,36 ,37 ] . A retrospective study of diabetic patients presenting with ischemic strokes showed that patients taking sulfonylureas fared significantly better than patients whose diabetes was managed with metformin, insulin [38] , and so on. A prospective trial of glibenclamide in TBI is anticipated to start soon.
The phenomenon of blast traumatic brain injury
The introduction of body armor, critical care, practice guidelines, transcranial Doppler (TCD), and interventional radiology during Operation Iraqi Freedom (OIF) has reduced mortality (the killed to wounded ratio is about 1 : 10) [2 ,39] . In addition to penetrating brain injury, Friedlander-like blast overpressure waves emanating from high explosives translate a significant quantity of mechanical, thermal, and electromagnetic energy to the brain directly through the cranium and indirectly through oscillating pressures in fluid-containing large blood vessels [40, 41] . In animal models, highfrequency (0.5-1.5 kHz) low-amplitude stress waves damage the blood-brain barrier, and low-frequency (<0.5 kHz) high-amplitude shear waves damage the gray white junction [2 ,42] . The latter can result in deafferentation of cortical columnar structure that is only visible through the integration of diffusion tensor imaging and magnetoencephalography [43 ] . The result is brain edema, cellular necrosis and apoptosis, cytoskeletal damage, diffuse axonal injury, and neuronal degeneration. A recent study from the Balkans by Cernak et al. [40] indicated long-term signs and symptoms reflecting CNS disorder in 30% of 665 patients sustaining blast overpressure. In this study, PTSD was noted in 11% of the patients. Similarly a survey of 2525 U.S. soldiers 3-4 months after their return from a year-long deployment to Iraq indicated a significant association between PTSD and mild TBI [5 ] . Of these soldiers, 124 (4.9%) reported loss of consciousness and 260 (10.3%) reported altered mental status. Of the soldiers reporting loss of consciousness, 43.9% had PTSD as compared with 27.3% of those who reported altered mental status. PTSD and depression were important mediators of the relationship between mild TBI and poor general health, missed workdays, and medical visits. The survey by Schneiderman et al.
[6] disclosed the incidence of PTSD in 2235 American veterans to be 11%. Almost 60% of the 320 000 Americans deployed have had some degree of blast overpressure TBI during OIF. In the severest form, blast overpressure results in subarachnoid hemorrhage, cytotoxic brain edema, or significant hyperemia within an hour that is responsive only to temporary decompressive craniectomy [44] . In a study by Armonda et al. [45] , the incidence of traumatic intracranial aneurysms in 47 victims of blast TBI was 35% and 47% suffered from cerebral vasospasm that could be relieved by angioplasty.
Failure of bench-to-bedside translation
Preclinical research during the past 30 years has helped our overall understanding of secondary injury cascades. More than 20 phase II or phase III prospective trials have assessed the merit of protecting neural tissues from well known phenomena such as oxidative stress, calcium, excitotoxicity, ischemic insults, and inflammatory cytokines [46] [47] [48] . Although none of the completed trials have shown favorable treatment effects, many more trials are ongoing or in early stages of commencement. These include trials on hypothermia [49 ] , progesterone [25, 26 ] , erythropoietin [50, 51] , citicoline [52] , cyclosporine A [53] , statins [54] , and magnesium [1, 55] . In a recent article by Margulies and Hicks [7 ], some of the major reasons cited for failure of clinical trials included: inadequate understanding of secondary injury mechanisms (e.g., translation of therapeutic windows and plasma levels between animals and humans); inadequate preclinical testing in multiple injury models, species, ages, and sexes; lack of thorough investigation of pharmacokinetics; a heterogeneous patient population; and inadequate functional assessment scales and biomarkers for injury progression and recovery. To improve overall treatment effect, the authors suggested combination therapies:
(1) Select therapies for use in combination that target multiple and complementary mechanisms of action. (2) Validate surrogate markers to monitor treatment effects on brain injury and recovery for all stages of therapy development (in vitro, animal, and human).
(3) Develop in-vitro, animal, and clinical platforms for coordinated studies across multiple laboratories. (4) Use efficient designs for trials and data analysis. (5) Be informed of the FDA regulations. (6) Adopt a uniform standard of care for clinical trials, and mimic these standards in preclinical studies. (7) Establish a shared database of positive and negative clinical and preclinical data.
International mission for prognosis and clinical trial design database
For more than 20 years, many randomized controlled trials have been performed to investigate the effectiveness of new therapies in patients with closed head injury [46, [55] [56] [57] [58] [59] [60] [61] [62] [63] . Recently, with the support of the National Institutes of Health (NIH), work groups put together a Top Priority Data Set (TPDS) composed of patient data collected during eight randomized trials and three observational studies. The data covered prehospitalization, resuscitation, acute care, follow-up, and outcome for 9025 patients. This database was used to test several hypothetical issues related to heterogeneity, design, and analysis of prognostic factors. Univariate and multivariate analysis indicated that the most important independent prognostic variables were age, Glasgow Coma Scale (GCS) motor response, abnormal papillary response to light, and computerized characteristics including Marshal Classification [9] . Other important variables were hypotension, hypoxia, coagulopathy, hemoglobin eye, and verbal components of the GCS, glucose, and platelets [9] . It was also learned that adjusting for seven covariates yielded up to a 28% potential reduction in trial size [8 ] .
Ongoing analyses on the potential benefits of ordinal analysis, such as proportional odds and sliding dichotomy, gave promising results with even larger potential reductions in trial size [8 ,64] .
Decompressive craniectomy
Although never studied prospectively, intracranial hypertension, if not managed properly, may result in bad outcome following TBI [65] [66] [67] . Up to 15% of patients with severe head injury and brain swelling do not respond to maximum medical management and may need secondtier therapies including decompressive craniectomy [49 ,68,69] . Decompressive craniectomy has played a significant role in OIF in mitigating deleterious effects of severe brain swelling following blast head injury [44] . Apart from interrupting intracranial hypertension, decompressive craniectomy increases compliance [70] , cerebral blood flow [71] , and brain oxygenation [72] . Compared to historical controls, class II and III studies indicate improved outcome after decompressive craniectomy [68, 73] Decompressive craniectomy resulted in a better outcome in patients with higher admission GCS score. In patients with mass lesions, ICP monitoring did not have a well defined role, and determinants of outcome were the volume of mass lesion and ischemic findings on preop or postop head computed tomography (CT). GCS outcome was better in patients with diffuse injury (40%) than in patients harboring mass lesions greater than 50 ml (36.5%) [68, 74 ] . Two ongoing randomized trials initiated in the United Kingdom (RESCUEicp) and Australia (DECRA) may determine if decompressive craniectomy is not only valuable in reducing intractable intracranial hypertension, but also whether it improves outcome after severe head injury [75, 76] .
Conclusion
In-depth understanding of secondary injury, well designed and adequate preclinical studies, detailed pharmacokinetics, analytical compensation for heterogeneity, and better tools for functional assessment seem to be the preferred direction for future randomized trials. Of significance is a call for combination therapies and a new multidimensional classification of TBI.
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